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Received May 21, 2012; accepted September 7, 2012AbstractBackground: Peritoneal dialysis (PD)-related peritonitis is a serious complication that typically leads to hospitalization, catheter loss, and even
mortality. Previous studies of the risk factors for peritonitis are discordant. To date, no biomarker associated with PD-related peritonitis has been
investigated. However, it has been shown that serum decoy receptor 3 (DcR3) is a valuable marker in predicting the outcome of several
inflammatory diseases. The aim of this study was to investigate whether serum DcR3 is a predictor of peritonitis in chronic PD patients.
Methods: We conducted a prospective cohort study of PD patients in the PD unit of a tertiary referral center from March 1 to November 30, 2007,
and followed up until December 31, 2009. Clinical and laboratory parameters were recorded and serum DcR3 was measured to assess risk
factors for developing PD-related peritonitis.
Results: A total of 77 patients (38 men and 39 women; mean age 58  13 years) were enrolled in this study. The average time on PD was 24.5
months and 46 patients (60%) were diabetic. The mean follow-up duration was 499  17 days. The rate of peritonitis incidence was 0.17
episodes per patient-year. Baseline serum DcR3 in 77 patients was 1.94  1.23 ng/mL. KaplaneMeier survival analysis showed that patients
with serum DcR3 > 1.8 ng/mL had a higher risk of peritonitis than those with serum DcR3 < 1.8 ng/mL ( p ¼ 0.016). The Cox proportional
hazard model further showed that high serum DcR3 (>1.8 ng/mL) was an independent risk factor for subsequent peritonitis (hazard ratio 3.61,
95% CI 1.17e11.08; p ¼ 0.03).
Conclusion: Serum DcR3 was associated with increased risk of PD-related peritonitis.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Peritoneal dialysis (PD) is a well-established treatment
modality for patients with end-stage renal disease (ESRD).
Despite advances in technology and improvements in dialysis
solutions, PD-related peritonitis remains the major complica-
tion of PD.1 Recent observations have shown that it was the* Corresponding author. Dr. Tung-Po Huang, Wei Gong Memorial Hospital,
128, Xinyi Road, Toufen, Miaoli 351, Taiwan, ROC.
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1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.09.009main cause of hospitalization,2 catheter loss,3 transfer to
hemodialysis,4 and death5 in PD patients. Therefore, identifi-
cation of specific risk factors associated with peritonitis in PD
patients would be important to help in reducing this major
dialysis-related complication. Several predictors have been
reported to be associated with PD-related peritonitis, including
age, gender, race, diabetes, obesity, low serum albumin, and
PD modality.6e8 At present, however, studies that examined
the risk factors for developing PD-related peritonitis are still
limited and conflicting. Moreover, peritonitis rates vary
substantially in recently published studies, from a high of 0.70hinese Medical Association. All rights reserved.
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per year in Taiwan.10 There is still no satisfactory explanation
for this variation. However, some authors have argued that it is
probably related in part to differences in training programs and
in the varieties of peritonitis prevention protocols used from
country to country.11 Therefore, identification of new predic-
tors for PD-related peritonitis remains an important
undertaking.
Decoy receptor 3 (DcR3) is a soluble receptor that lacks
a transmembrane domain and neutralizes three members of the
tumor necrosis factor (TNF) superfamily, including Fas ligand
(FasL), LIGHT (homologous to lymphtoxins, exhibits inducible
expression, competes with HSV glycoprotein D for herpes
simplex virus entrymediator, and expressed by T lymphocytes),
and TNF-like molecule 1A (TL1A).12 DcR3 is now regarded as
a novel immunosuppressant because of its ability to block the
activities of TL1A, LIGHT, and FasL, as well as its non-decoy
functions.12 In particular, DcR3 can attenuate the host
immune response and modulate the autoimmune response and
other inflammatory reactions. DcR3 is not detectable in most
normal tissues, but it is upregulated in various cancers and
inflammatory conditions. Serum DcR3 levels are elevated in
colon cancer,13 renal cell cancer,14 systemic lupus eryth-
ematosus,15 silicosis,16 and in patients with chronic kidney
disease (CKD).17 CKD PD patients are characterized by
a significant inflammatory status.18 However, DcR3 expression
in PD patients has not been investigated previously. In a study on
acute respiratory distress syndrome (ARDS) patients, high
plasma levels of DcR3 correlated with later development of
multiple organ failure and can independently predict 28-day
mortality.19 Therefore, serum DcR3 is a valuable marker in
predicting the outcome of inflammatory diseases. The aimof our
study was to investigate whether serum DcR3 is a predictor of
peritonitis in chronic PD patients.
2. Methods2.1. PatientsPatients undergoing peritoneal dialysis treatment at the dial-
ysis center of Taipei Branch, Buddhist Tzu Chi General Hospital
were recruited between March 1, 2007 and November 30, 2007,
and followed up until December 31, 2009. The inclusion criteria
for peritoneal dialysis patients were over 18 years of age, PD
treatment for at least 90 days, no chronic inflammation or
malignancy, no peritonitis within 30 days, and no active infec-
tions such as pneumonia and infective endocarditis. All patients
used the twin-bag system with commercially available glucose-
based dialysis solutions (Dianeal; Baxter, Singapore). The
research protocol was approved by the Institutional Review
Board of Taipei Branch, Buddhist Tzu Chi General Hospital.
Informed consent was obtained from all patients.2.2. Clinical data collection and blood samplingFor our study subjects, diagnosis of PD-related peritonitis
was according to International Society for PeritonealDialysis (ISPD) criteria when two of the following three
findings were presented: abdominal pain, cloudy effluent,
and effluent white blood cell count exceeding 100/mL with at
least 50% neutrophils.20 Analyses of cultures collected from
all cases with peritonitis were carried out at the Microbi-
ology Laboratory of Taipei Branch, Buddhist Tzu Chi
General Hospital.
In the prospective cohort study, baseline clinical data were
recorded by patient chart review, including age, gender, type
of PD regimen, and time on dialysis. Associated comorbid-
ities, including diabetes mellitus, were also recorded. Body
weight and blood pressure were collected from patient diaries
and clinic visits. All laboratory data, including serum albumin,
hemoglobin, high-sensitivity C-reactive protein (hs-CRP) and
serum DcR3, were checked at the beginning of the study.
Serum DcR3 was measured using a commercially available
ELISA kit (BioVendor, Brno, Czech Republic) according to
the manufacturer’s instructions.172.3. Statistical analysisDescriptive statistics include mean  SD values for
continuous data and percentages for categorical data. For
between-group comparisons, the Student t test was used for
normally distributed data and the ManneWhitney rank sum
test for data with a non-normal distribution. Categorical
variables were compared using the Pearson c2 test. Receiver
operating characteristics (ROC) analysis was used to find the
optimal DcR3 cutoff value. A peritonitis-free survival curve
was generated by the KaplaneMeier method and we analyzed
hazard ratios using the Cox proportional hazards method. The
level of significance was set at p < 0.05 for all tests. Statistical
analysis was performed using the computer software Statis-
tical Package for the Social Sciences (SPSS 17.0; SPSS Inc.,
Chicago, IL, USA).
3. Results
Seventy-seven PD patients were enrolled in the study. Their
mean age was 58  13 years and the average time on dialysis
was 24.5  10.5 months. Thirty-eight (49%) patients were
male and 46 (60%) patients were diabetic. The mean follow-
up duration was 499  17 days. Overall, 15 episodes of
peritonitis were identified. Coagulase-negative Staphylococcus
(26.7%) was the most common causative organism (Table 1).
The incidence rate for peritonitis was 0.17 episodes per
patient-year.
Accordingly, patients were stratified into two groups:
a peritonitis-free group (n ¼ 62) and a peritonitis group
(n ¼ 15). Table 2 presents the differences between these
groups. Patients who had peritonitis had significantly higher
levels of serum DcR3 (2.63  1.67 vs. 1.78  1.05 ng/mL;
p ¼ 0.01). There were no significant differences between the
groups in terms of age, gender, presence of diabetes and
hypertension, dialysis modality (automated PD, APD; or
continuous ambulatory PD, CAPD), PD solution (standard
glucose-based solution or icodextrin), baseline serum albumin,
Table 1
Micro-organisms in PD patients with peritonitis.
Organisms n %
Gram-positive organisms
Coagulase-negative Staphylococcus 4 26.7
Staphylococcus aureus 3 20
Streptococcus 1 6.7
Enterococcus 1 6.7
Gram-negative organisms
Escherichia coli 3 20
Pseudomonas aeruginosa 1 6.7
Serratia 1 6.7
Culture negative 1 6.7
Total 15 100
Fig. 1. KaplaneMeier estimate of PD-related peritonitis-free cumulative
survival according to serum DcR3 at baseline.
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correlated with albumin (r ¼ 0.500; p < 0.001) and posi-
tively correlated with hs-CRP (r ¼ 0.262; p ¼ 0.02).
ROC curve analysis revealed that serum DcR3 of 1.8 ng/
mL was the best cutoff value in predicting PD-related peri-
tonitis, with sensitivity of 76.7% and specificity of 69.7%.
KaplaneMeier analysis showed that time to the first PD
peritonitis episode was significantly longer in patients with
serum DcR3 < 1.8 ng/mL than in those with serum
DcR3 > 1.8 ng/mL ( p ¼ 0.016; Fig. 1). In univariate Cox
proportional hazards analysis, serum DcR3 was significantly
associated with a higher likelihood of peritonitis (Table 3).
Otherwise, age, gender, diabetes mellitus, time on PD,
albumin, and hs-CRP were not related to peritonitis. After
adjustment for age, gender, and other potential confounders,
DcR3 was still significantly associated with PD-related peri-
tonitis, with a hazard ratio of 3.61 (95% CI, 1.17e11.08,
p ¼ 0.03).Table 2
Comparison of clinical and laboratory data between the peritonitis and
peritonitis-free groups.
Parameter Peritonitis
(n ¼ 15)
Peritonitis-free
(n ¼ 62)
p
Age (y) 58.4  11.4 57.9  12.3 0.50
Male 7 (46.7) 31 (50.0) 0.30
Diabetes 9 (60.0) 37 (59.6) 0.80
Hypertension 13 (86.7) 53 (85.4) 0.80
Dialysis modality
APD 4 (26.7) 19 (30.6) 0.10
CAPD 11 (73.3) 43 (69.4)
Dialysis solution
Standard 12 (80.0) 47 (75.8) 0.20
Icodextrin 3 (20.0) 15 (24.2)
Serum albumin (g/dL) 3.45  0.54 3.66  0.43 0.10
Hemoglobin (mg/dL) 10.56  1.96 10.77  2.01 0.20
Serum hs-CRP (mg/dL) 0.41 (0.20e1.26) 0.35 (0.1e0.79) 0.30
Daily urine volume (L) 0.55 (0.36e0.75) 0.50 (0.15e0.84) 0.80
Total Kt/V 2.01  0.43 2.07  0.46 0.70
Serum DcR3 (ng/mL) 2.63  1.67 1.78  1.05 0.01
Follow-up duration (d) 480  131 504  141 0.70
Peritonitis-free time (d) 283  193 552  117 <0.001
Data are presented as mean  SD, n (%), or median (interquartile range).
APD ¼ automated peritoneal dialysis; CAPD ¼ continuous ambulatory
peritoneal dialysis.4. Discussion
The most compelling finding in our study is that elevated
serum DcR3 was associated with increased risk of PD-related
peritonitis. To the best of our knowledge, our study is the first
to focus on serum DcR3 as a biomarker for PD-related
peritonitis.
PD-related peritonitis is a serious complication of PD.
Although less than 4% of peritonitis cases directly result in
death, PD-related peritonitis is a contributing factor to 16% of
the deaths in PD patients.21 Therefore, identification of high-
risk patients for PD-related peritonitis is very important to
doctors, who can devote more efforts and resources to reduce
the risk of infection in PD programs.
In this study, several conventional risk factors such as
hypoalbuminemia, diabetes mellitus, female gender, age, and
PD modality (APD or CAPD) were not associated with an
increased risk of peritonitis. ISPD recommendations (revised
in 2010) suggest that the rate of peritonitis for a center shouldTable 3
Crude and adjusted hazard ratios for serum DcR3 for PD-related peritonitis.
Parameter Crude HR
(95% CI)
p Adjusted HRa
(95% CI)
p
Age (per y) 1.01 (0.96e1.06) 0.68 1.09 (0.34e3.45) 0.89
Female gender 2.08 (0.71e6.09) 0.18 2.33 (0.75e7.14) 0.14
Diabetes mellitus 2.66 (0.73e9.62) 0.14 2.58 (0.71e9.34) 0.15
Time on PD (per d) 0.99 (0.99e1.00) 0.07 0.99 (0.98e1.00) 0.12
Albumin (>3.5 vs.
<3.5 g/dL)
0.40 (0.15e1.13) 0.09 0.58 (0.20e1.74) 0.33
Hs-CRP (>0.5 vs.
<0.5 mg/dL)
1.55 (0.56e4.27) 0.40 1.021 (0.75e2.40) 0.36
Serum DcR3 (>1.8
vs. <1.8 ng/mL)
3.47 (1.17e10.30) 0.02 3.61 (1.17e11.08) 0.03
CI ¼ confidence interval; DcR3 ¼ decoy receptor 3; HR ¼ hazard ratio;
PD ¼ peritoneal dialysis.
a Adjusted for age, gender, diabetes, time on PD, serum albumin, and hs-
CRP in multivariate analysis.
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however, that clinicians should still strive to achieve a lower
rate of 0.23 episodes per patient-year. Compared with recent
studies on PD-related peritonitis,11 the rate of peritonitis in our
study was relatively low (0.17 episodes per patient-year).
There are huge variations in peritonitis rates for different
care providers, centers, and countries, and satisfactory expla-
nations for such variations are still lacking. These differences
might in part account for the failure to reconfirm conventional
risk factors for PD-related peritonitis in our study. Taking
serum albumin for example, several studies have demonstrated
that hypoalbuminemia is an independent predictor of subse-
quent peritonitis.22,23 Increased risk of PD-related peritonitis
with low serum albumin may be attributed to a compromised
immune response as a result of hypoalbuminemia and
malnutrition.23,24 However, the mean serum albumin in our
study (3.6 g/dL) was higher than that in some other studies
(3.1 g/dL).25 Other investigators could not show serum
albumin (average 3.3e3.6 g/dL) as a risk factor for PD-related
peritonitis in recent studies,26,27 which is consistent with our
findings.
Diabetes mellitus is the major cause of ESRD in patients
undergoing renal replacement therapy in Taiwan28 and
worldwide.29 Reports on whether diabetes is a risk factor for
PD-related peritonitis are still conflicting. Some studies have
shown that diabetes mellitus is associated with compromised
immune response of the peritoneum in PD patients.24,26,30
On the contrary, diabetes mellitus was not identified as
a risk factor in some studies,6,27 including the present study.
Part of the reason for this is better control of blood glucose
in these patients to ameliorate vulnerability to peritonitis.
A previous study found a lower rate of peritonitis in
patients treated with APD compared to patients treated with
CAPD.31 In our study, the type of dialysis technique did not
influence patient survival. In either case, nonrandomized
treatment assignment makes it difficult to interpret its role in
increased risk. Furthermore, other factors such as age, gender,
and time on dialysis are still controversial as risk factors for
PD-related peritonitis in previous studies.6,9,11,26,27,30
In the present study, serum DcR3 was associated with the
risk of PD-related peritonitis. High serum DcR3 might imply
that PD patients were experiencing sustained low-grade
inflammation. DcR3 has been recognized as a novel immu-
nosuppressant with a biological function involving modulation
of the immune response and inflammatory reactions. DcR3
can suppress the Th1 response and attenuate cell-mediated
immunity in vitro.32 When DcR3 transgenic mice were
infected with bacteria, interferon-gamma expression was
attenuated and susceptibility to infection increased.32 In
in vitro studies, phagocytic activity towards immune
complexes and apoptotic bodies and the production of free
radicals and proinflammatory cytokines in response to lipo-
polysaccharide were impaired in DcR3-treated macro-
phages.33 DcR3 also inhibited major histocompatibility
complex II expression via epigenetic regulation.33 In humans,
DcR3 in serum or tissue correlated with poor prognosis and/or
resistance to treatment in cancer patients, including colorectalcancer,13 renal cell carcinoma,14 and ovarian cancer.34 More-
over, DcR3 levels are elevated in infection and inflammatory
diseases, such as bacterial infection,35 acute appendicitis,36
systemic lupus erythematosus,15 and silicosis.16 Therefore,
DcR3 can be a biomarker for disease severity or a predictor for
disease outcomes. In patients with systemic sclerosis, serum
DcR3 was associated with later development of pulmonary
arterial hypertension.37 In another study involving ARDS
patients, higher DcR3 (>3 ng/mL) was correlated with
subsequent development of multiple organ failure and inde-
pendently predicted the 28-day mortality rate. Sustained low-
grade systemic inflammation is highly prevalent in CKD and is
even more severe in PD patients.38,39 It is an important
prognostic factor for morbidity and mortality in PD patients.
Chronic inflammation is closely related to malnutrition,
characterized by elevated CRP and a decrease in albumin
level, the so-called malnutritioneinflammationeatheroscle-
rosis syndrome.40 The mechanism underlying inflamma-
tionemalnutrition correlation is multifactorial and is yet to be
elucidated. In our study, serum DcR3 was inversely related to
albumin and positively related to hs-CRP, which suggests that
DcR3 might serve as a marker for malnutritioneinflammation
status. Taken together, results suggest that DcR3 may involve
pathologic processes that deregulate the immune system.
Unlike other retrospective or database-derived studies,
the strength of our present study is that it is a prospective
observational study. However, there are some limitations to
the study. All the PD patients were classified as having
either high or low serum DcR3 based on a single blood test,
without follow-up levels being recorded. In addition, the
small population size and the short follow-up period suggest
that caution is required in deriving conclusions and statis-
tical significance. We also did not collect and analyze
information on the impact of patient education level,
cognitive function, and nasal carriage Staphylococcus
aureus status. These factors have been implicated in
previous studies.41,42 Larger series and longer follow-up
studies are required to better understand the association
between serum DcR3 and PD-related peritonitis. At this
point, the benefits of routine screening for serum DcR3 in
a PD unit have not been fully examined and require addi-
tional research. Furthermore, it will also be important to
clarify the pathomechanism involved between DcR3 and PD
peritonitis.
In conclusion, our study suggests that serum DcR3 might
be suitable as a biomarker for PD-related peritonitis. Further
large cohort studies are needed to elucidate this possibility and
further investigation is merited to examine the pathogenesis of
DcR3 in PD-related peritonitis.
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